REG - Ergomed plc - Disclosure of Directors' Appointments <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

19/08/2016 11:18

RNS Number : 1223H
Ergomed plc
15 August 2016
PRESS RELEASE
FOR IMMEDIATE RELEASE
15 August 2016
Ergomed Plc
Disclosure of Directors' Appointments
Pursuant to AIM Rule 17 and Schedule 2 Annex III of the AIM Rules, Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company') provides the following updated disclosures relating to its directors. 
Rolf Stahel (Chairman):
Current Directorships 
Ergomed Plc 
Chesyl Pharma Limited
Midatech Pharma Plc 
Connexios Life Sciences Pvt Limited 
Previous Directorships (last five years) 
Midatech Limited
Newron Pharmaceuticals Spa 
Cosmo Pharmaceuticals Spa 
Eusa Pharma Inc
Miroslav Reljanovic (Chief Executive Officer):
Current Directorships
Ergomed Plc
Ergomed Clinical Research Limited
Primevigilance Limited
Sound Opinion Limited
Ergomed Istrazivanja d.o.o.
Ergomed GmbH
Ergomed LLC
Ergomed Clinical Research FZ LLC
Ergomed Clinical Research, Inc
Ergomed d.o.o.
Ksa Jv Ergomed
Ergomed Virtuoso Sarl
Lincetovo d.o.o.
Ljetnikovac Lantana d.o.o.
Haemostatix Limited
Stephen Stamp (Chief Financial Officer):
Current Directorships
Ergomed Plc
Storm Pharmaceuticals, Inc
Haemostatix Limited
Neil Clark (Executive Director):
Current Directorships
Ergomed Plc
Primevigilance Limited
Ergomed Clinical Research Limited
Sound Opinion Limited
Ergomed GmbH
Primevigilance Inc
Ksa Jv Ergomed
Ergomed Virtuoso Sarl
Andrew Mackie (Chief Business Officer):
Current Directorships
Ergomed Plc
Montagu Pharma Limited
Haemostatix Limited
Previous Directorships (last five years)
Am Pharma Consulting Limited
Peter George (Non-Executive Director):
Current Directorships
Ergomed Plc
Clinigen Clinical Trials Limited
Clinigen CTS Limited
Clinigen GAP Limited
Clinigen Group Plc
Clinigen Healthcare Limited
Clinigen Pharma Limited
Clinigen Sp Limited
Idis Ga Limited
Idis Group Limited
Idis Limited
Idis Ma Limited
Idis Pharma Limited
Idis Trustee (Uk) Limited
Idis Inc (US)
Keats Healthcare Limited
Xpg Limited
Wichtig International Limited
454 Daniel and Donna Lda
Clinigen CTS Inc (US)
Peter George was a director of UCT (UK) Limited from 26 July 1999 until its dissolution on 6 November 2004 following a voluntary creditors liquidation.
Christopher Collins (Non-Executive Director):
Current Directorships
Ergomed Plc
Rx Securities Limited
Eidos Pharma Limited
Previous Directorships (last five years)
Nomura Code Securities Limited
- ENDS -
Enquiries:
Ergomed Plc
Miroslav Reljanovic (Chief Executive Officer)
Stephen Stamp (Chief Financial Officer)
Tel: +44 (0) 1483 503205


Numis Securities Limited
Michael Meade / Freddie Barnfield (Nominated Adviser) 
James Black (Joint Broker)
Tel: +44 (0) 20 7260 1000


Stifel Nicolaus Europe Limited
Jonathan Senior (Joint Broker)
Tel: +44 (0) 20 7710 7600


FTI Consulting
Simon Conway / Mo Noonan / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries. 
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings. For further information, visit: http://ergomedplc.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDNGGUMARUPQGMC